NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

BioInvent International AB (publ) (ST: BINV)

 
BINV Technical Analysis
4
As on 1st Apr 2025 BINV STOCK Price closed @ 29.10 and we RECOMMEND Buy for LONG-TERM with Stoploss of 25.08 & Strong Buy for SHORT-TERM with Stoploss of 16.03 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

BINVSTOCK Price

Open 32.70 Change Price %
High 32.70 1 Day -1.70 -5.52
Low 28.60 1 Week -2.55 -8.06
Close 29.10 1 Month 5.15 21.50
Volume 176580 1 Year 14.34 97.15
52 Week High 50.80 | 52 Week Low 14.14
 
ST Sweden Most Active Stocks
ATORX 0.01 0.00%
FING-B 0.01 0.00%
QUIA 0.01 %
LUNE 21.97 6.65%
SBB-B 3.46 2.37%
QLINEA 0.04 0.00%
FNOX 85.70 -1.47%
XBRANE 0.21 0.00%
ONCO 1.66 12.16%
EURA 0.01 0.00%
 
ST Sweden Top Gainers Stocks
KOPY 0.10 150.00%
SECI 0.03 50.00%
SECI 0.03 50.00%
ADVBOX 0.03 50.00%
SPIFF 0.04 33.33%
LCLEAN 0.35 16.67%
INT 46.10 16.56%
INT 46.10 16.56%
INT 46.10 16.56%
CFISH 0.85 14.86%
 
ST Sweden Top Losers Stocks
ZICC 0.25 -34.21%
AUR 0.82 -31.67%
AUR 0.82 -31.67%
ALLR 1.55 -26.54%
ASAP 0.03 -25.00%
ASAP 0.03 -25.00%
ASAP 0.03 -25.00%
GIAB 0.10 -23.08%
PHARM 0.56 -16.42%
PHARM 0.56 -16.42%
 
 
BINV
Daily Charts
BINV
Intraday Charts
Whats New @
Bazaartrend
BINV
Free Analysis
 
BINV Important Levels Intraday
RESISTANCE37.00
RESISTANCE34.47
RESISTANCE32.90
RESISTANCE31.33
SUPPORT26.87
SUPPORT25.30
SUPPORT23.73
SUPPORT21.20
 
BINV Forecast April 2025
4th UP Forecast32.76
3rd UP Forecast31.59
2nd UP Forecast30.86
1st UP Forecast30.14
1st DOWN Forecast28.06
2nd DOWN Forecast27.34
3rd DOWN Forecast26.61
4th DOWN Forecast25.44
 
BINV Weekly Forecast
4th UP Forecast31.95
3rd UP Forecast31.04
2nd UP Forecast30.47
1st UP Forecast29.91
1st DOWN Forecast28.29
2nd DOWN Forecast27.73
3rd DOWN Forecast27.16
4th DOWN Forecast26.25
 
BINV Forecast2025
4th UP Forecast100.01
3rd UP Forecast77.27
2nd UP Forecast63.21
1st UP Forecast49.16
1st DOWN Forecast9.04
2nd DOWN Forecast-5.01
3rd DOWN Forecast-19.07
4th DOWN Forecast-41.81
 
 
BINV Other Details
Segment EQ
Market Capital 2163430656.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
BINV Address
BINV
 
BINV Latest News
 
Your Comments and Response on BioInvent International AB (publ)
 
BINV Business Profile
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, rest of Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206, a monoclonal antibody targeting CD32b, which is in Phase I/IIa clinical trials in patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia. The company is also developing cancer-associated regulatory T cells which modulate the immune system; and BI-1808 and BI-1910, an anti-TNFR2 antibody for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL). It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumour-associated myeloid cells; partnership and collaboration with Transgene to co-develop multi-functional oncolytic viruses for treatment of solid tumors; and a collaboration agreement with SkylineDx to characterize the gene expression and immunological signatures in tumors of patients pre-and post-treatment with BI-1206. The Company was incorporated in 1996 and is headquartered in Lund, Sweden. Address: The Gamma Building, Lund, Sweden, 223 70
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service